source
- Bambusa Therapeutics exceeds IPO target raising $169 million, while Aspen Neuroscience falls short with $141 millionBambusa Therapeutics announced that its initial public offering was upsized, selling more shares at the midpoint of its $15‑$17 range and raising about $168.9 million, exceeding the $150.4 million…
- Roche launches VENTANA BAP1 test to improve mesothelioma diagnosisRoche announced the global launch of its VENTANA BAP1 (SP527) test, an automated ready‑to‑use immunohistochemistry assay designed for differential diagnosis of mesothelioma. The assay targets the…